Sign in
PHVS Stock Price, Chart, Stats & News
Pharvaris BV
Save
Pharvaris BV (PHVS) does not currently pay a dividend.
2.45B
Market cap
–
Current P/E
–
Forward P/E
PHVS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -1.00% |
ROA | -48.99% |
ROE | -67.11% |
D/E | 0.00x |
Interest coverage ratio | – |
PHVS valuation
P/E | – |
P/S | – |
P/B | 4.73x |
P/CF | -11.01x |
P/FCF | -11.46x |
P/OCF | -11.01x |
PEG | -1.86x |
EV multiple | -12.04x |
About
Pharvaris N. V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Similar securities
Based on sector and market capitalization
Report issue